Ungated Post | 06 Mar 2020
Making cells better: Complex challenges drive innovation in cell and gene therapy manufacturing
The processes required for C> manufacture are wholly new and extremely complex. As production and delivery of these new therapies to patients are still nascent, biopharmaceutical companies will need to harness new technological advances and innovate continuously in the manufacturing process.
Large capital investments in the industry are likely to bring breakthroughs in the coming years that will standardise processes, simplify delivery logistics, boost efficiency, and increase competition.
Our Thought Leadership team produces original, evidence-based research made accessible to decision-makers and opinion leaders. Principals for this project included:
Oxford Economics’ team is expert at applying advanced economic tools that provide valuable insights into today’s most pressing business, financial, and policy issues.
To find out more about our capabilities, contact:
EMEA
Paul Donnelly
020 3910 8000
Email
Americas
Jeffrey Klonoski
+1 646 503 3048
Email
Asia
Christie Tang
+852 3974 8841
Email
Related Services
Post
KPMG M&A Outlook 2026: Between Uncertainty, Resilience, and Seizing Opportunities
Discover how Germany’s M&A landscape is evolving – with a focus on growth, AI and post-merger value creation.
Find Out More
Post
Silver, the next generation metal
This report highlights the critical role silver plays in data centres and artificial intelligence (AI), automotive and electric vehicles (EVs), and solar energy photovoltaics (PVs). With these sectors expected to expand significantly over the coming years, we expect future silver demand to be strong.
Find Out More
Post
Powering the UK Data Boom: The Nuclear Solution to the UK’s Data Centre Energy Crunch
The UK’s data centre sector is expanding rapidly as digitalisation, cloud computing, and artificial intelligence (AI) drive surging demand for high-performance computing infrastructure.
Find Out More
